Cambridge, MA, USA and Paris, France, March 27, 2023 – Tersan Pharmaceuticals Ltd, the leading Al-driven precision medicine company, has announced the appointment of Professor Jacques Touchon to its Scientific Advisory Board.

Tersan is pleased to announce that Professor Jacques Touchon, a world renown neurologist, Alzheimer’s Disease specialist and co-founder of the Clinical Trials on Alzheimer’s Disease (CTAD) international convention has joined its scientific advisory board.

Professor Touchon will help bolster Tersan Pharmaceuticals Ltd’s clinical expertise in the field of CNS diseases and expand the company’s collaborations internationally. He will be joining on Tersan’s SAB Professor Jean Sallantin, a pioneer of French bioinformatics and former Director of the Artificial Intelligence Laboratories at the LIRMM CNRS and Dr Alain Commerçon, former Senior Research Director within the Lead Generation organization at Sanofi-Aventis.

Professor Touchon received his Medical Degree in 1979 and his specialty in Neurology in 1992 from the Medical School of Montpellier. He has been a Professor of Neurology at the Medical School University since 1990 and Dean of the School of Medicine (2000-10). In 2004, he was appointed Chief of Neurology at Montpellier University Research Hospital and was the director of the Center for Memory Resources and Research for the Languedoc-Roussillon region. In 1999 he was awarded the academic palms for his research on Alzheimer’s Disease and the Pinel Prize and was also the recipient of the Légion d’Honneur in 2007. He is currently the Editor in chief of the Journal of Prevention of Alzheimer’s Disease (JPAD).

Professor Jacques Touchon commented: “we are living in the most exciting period as we start to see breakthroughs in the development of drugs that fight neurodegenerative diseases such as Alzheimer’s.  Looking at Tersan’s track record, I strongly believe that explainable Artificial Intelligence technologies as pioneered by Tersan can transform and accelerate the development of highly needed new drugs to these patients. I am excited to join the SAB alongside my renowned colleagues”. .

“Tersan Pharmaceuticals Ltd is proud to welcome Professor Jacques Touchon to its Scientific Advisory Board. Professor Touchon will be vital in helping us align Tersan Pharmaceuticals Ltd’s explainable AI platform to the needs of CNS drug development and expand our existing collaborations in this space, at one of the most exciting times in the history of drug development in CNS.” Commented Mohammad Afshar, MD, Co-founder and CEO of Tersan Pharmaceuticals Ltd.

• • • – Download the Press Release here

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.

 
Tersan Pharmaceuticals Ltd Media
Thomas Turcat

Tersan Pharmaceuticals Ltd Business Development
Marion Soto, Vice President, Business Development
m.soto@tersanpharm.com

<p>The post Tersan Pharmaceuticals Ltd strengthens SAB with appointment of world-leading Neurologist Jacques Touchon first appeared on Tersan Pharmaceuticals Ltd.</p>

• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed

Cambridge, MA, USA and Paris, France, November 30^th, 2022 – Tersan Pharmaceuticals Ltd, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results from a post hoc analysis of CY6463 first-in-human studies at the 2022 Clinical Trials On Alzheimer’s Disease (CTAD) international conference held in San Francisco, USA.

Cyclerion Therapeutics’ CY6463 is a first-in-class, CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that modulates a key node in a fundamental signaling pathway. CY6463 has been evaluated in two Phase 1 studies in healthy volunteers as well as signal-seeking patient studies in the rare mitochondrial disease, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) and in CIAS (cognitive impairment associated with schizophrenia); a study in AD (Alzheimer’s disease) is ongoing. Cyclerion is advancing CY6463  for the treatment of rare mitochondrial diseases.

A total of 134 healthy participants were enrolled across two randomized, placebo-controlled, Phase 1 studies in which single-ascending doses, multiple-ascending doses, food effect (crossover design) and the pharmacology of CY6463 (crossover design) were evaluated. In each study, safety, pharmacokinetic, and endpoints assessments were collected at baseline and at the end of dosing. Previously reported favorable safety profile of CY6463 was confirmed, with no major adverse events.

Age, certain neurophysiological measures, and high systolic blood pressure at baseline were identified with an increased response for the endpoints.

A systematic analysis of both trials using Tersan’s KEM® (Knowledge Extraction & Management) eXplainable AI platform revealed the impact of higher dose of CY6463 on 5 endpoints related to spatial learning (Milner Maze Test speed and accuracy,  p=0.004 and p=0.045), brain activity (electroencephalography: increased alpha power, eyes closed, p = 0.003), inflammation (Matrix Metalloproteinase 3, p = 0.008) and target engagement (cyclic guanosine monophosphate, p=0.019), thus demonstrating the potential of CY6463 for the treatment of multiple neurological diseases.

Tersan’s KEM® also generated new hypotheses of patient-selection biomarkers that were linked with improved response; notably, age greater than 49 years old was linked with greater improvement in Milner Maze Test (speed p=0.095, accuracy p=0.047) and increase in effect size (Cohen’s d) by 41% and 118% respectively, while baseline systolic blood pressure greater than or equal to 121 mmHg was linked with greater improvement in Milner Maze Test (speed p=0.055, accuracy p=0.052) and increase in effect size by 86% and 157% respectively.

This analysis of Phase 1 data in healthy participants demonstrates the ability of eXplainable AI tools, such as KEM®, to integrate and analyze broad and heterogeneous sources of data from different trials, to provide insight into a drug’s mechanism of action, to generate testable hypotheses, and to guide the optimal design of the next steps in clinical development.

“We are very pleased to report initial results from our collaboration with the Cyclerion team that illustrate the power of integrating our xAI driven approach very early in clinical development. Our first evidence of clinical improvement of endpoints relevant in multiple diseases as well as the systematic identification of candidate patient selection criteria will help the design of next-phase studies with higher probability of success” commented Mohammad Afshar, Tersan Pharmaceuticals Ltd CEO.

---

References:

• • – ClinicalTrials.gov Identifiers: NCT03856827, NCT04240158

• • • – Poster: CY6463 administration in healthy participants was associated with improvements in Alzheimer’s disease relevant biomarkers based on a systematic analysis of multiple Phase 1 clinical trials using KEM® eXplainable AI.download here

• • • – Download the Press Release here

For further information, please contact:  Email: info@tersanpharm.com

---

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.

Further information is available at www.tersanpharm.com 
Tersan Pharmaceuticals Ltd Media
Thomas Turcat
t.turcat@tersanpharm.com

Tersan Pharmaceuticals Ltd Business Development
Marion Soto, Vice President, Business Development
m.soto@tersanpharm.com

<p>The post CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials ​ first appeared on Tersan Pharmaceuticals Ltd.</p>

Blarcamesine significantly restores functionality in key molecular pathways including Alzheimer’s and Parkinson’s disease, KEM® xAI analysis shows.

Cambridge, MA, USA and Paris, France, October 4^th, 2022 – Tersan Pharmaceuticals Ltd, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study.

Initial results were presented by Tersan Pharmaceuticals Ltd at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in collaboration with Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of CNS diseases.

Building on extensive multi-omic analysis using Tersan’s KEM® (Knowledge Extraction and Management) AI platform, the findings further establish blarcamesine as a potent modulator of key pathways in multiple neuro-degenerative diseases and provide additional insight into its molecular mechanism of action. Blarcamesine (ANAVEX®2-73) is a novel oral selective sigma-1 receptor (SIGMAR1) agonist. It was previously investigated in a clinical Phase 2a study in Alzheimer’s disease in which blarcamesine resulted in a lower rate of both cognitive and functional decline.

 

Following the positive results of this study, a translational approach led to investigating blarcamesine in an international, double-blind, multicenter, placebo-controlled Phase 2 clinical study of 14-week duration in 132 patients with Parkinson’s disease dementia (PDD). The analysis shows that blarcamesine significantly restores functionality in key pathways including Alzheimer’s disease, Parkinson’s disease. Expression levels of pathological down-regulated neurodegenerative genes of both Alzheimer’s and Parkinson’s were significantly reactivated by the therapeutic effect of ANAVEX®2-73 (p<0.005). Neurodegenerative pathways were identified as significantly overrepresented. Importantly, Down-regulation of genes involved with neurodegeneration was observed in the placebo arm, however, was compensated in the blarcamesine arm.

 

Whole blood transcriptomics analysis (RNAseq, 14,150 genes) was performed at baseline and end of study (Week 14). The KEM® platform was used to identify clusters of genes that show a correlated expression change across patients and timepoints. In addition, Tersan Pharmaceuticals Ltd identified a novel gene network that is differentially expressed in Parkinson’s disease dementia (PDD) patients treated with ANAVEX®2-73 compared to placebo after 14 weeks of treatment.

Tersan Pharmaceuticals Ltd’s CEO Mohammad Afshar comments: “This first AI-driven pathway analysis in Parkinson’s disease dementia allows us to understand the intersection between a specific drug and patient biology. It further illustrates the power of KEM® Explainable AI to accelerate and increase the probability of success of precision medicine translational drug development through the better understanding of gene pathways in specific indications.”

The identification of a gene network as the blarcamesine response pathway lays the foundation to better understand the mechanism of action at the molecular level of blarcamesine. It is thus unlocking characterization of responders based on molecular profiling, as well as identification of new indications in neurodegenerative and other disorders.

 

---

References:

• – Poster: Study of the Mechanism of Action of blarcamesine (ANAVEX®2-73): Whole Blood Transcriptomics Analysis (RNAseq) Identifies Treatment Impact on Compensatory Pathways by Restoring Key Neurodegenerative Pathways Functionality, including Alzheimer’s and Parkinson’s Disease Pathways  (ClinicalTrials.gov Identifier: NCT04575259) download here

• – Download the Press Release here

For further information, please contact: 
Email: info@tersanpharm.com

---

About Tersan Pharmaceuticals Ltd

 

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. 

Further information is available at www.tersanpharm.com 

<p>The post AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX®2-73) in restoring key neurodegenerative pathways first appeared on Tersan Pharmaceuticals Ltd.</p>

Marion and Bertrand will be bringing their commercial and financial experience to further structure Tersan’s exponential growth, as the company continues to expand its xAI-driven drug development partnerships in Oncology, CNS, auto-immune, gastro-enterology and other therapeutic areas, as well as its Real-World Evidence business leveraging its 8 Billion+ records patient data assets.

Bertrand Lellouche is an experienced financial and business development executive. Prior to joining Tersan, Bertrand was the CFO of Promethera Biosciences, and led the company’s first European Listing Validation on the Tokyo Stock Exchange in 2020. Over the past three decades, Bertrand has acted as CFO & Executive Advisor for innovative and growing companies, with an emphasis in the Life Sciences, and has been involved in significant M&A, financing, and IPOs on the largest markets (USA-EU-Asia). He holds a Master of Science in International Management.

Dr Marion Soto joins Tersan Pharmaceuticals Ltd as Vice President of Business Development. Prior to Tersan, Marion was Director of Business Development, leading business activities and strategy for Ysopia Bioscience, a clinical-stage microbiome biotech. Prior to her business development role, Marion was Drug Development Lead, driving preclinical programs to clinic, including the Ysopia’s lead program in metabolic diseases. A former fellow of the Harvard Medical School affiliated Ronald Kahn Laboratory at Joslin Diabetes Center, Boston, USA, Marion has a decade-long experience in biotechnology and pharmaceutical business development. A graduate of the Ecole Polytechnique, Paris, she holds a Ph.D. in Nutrition & Neurobiology from AgroParisTech, Paris-Saclay University.

 “We are delighted to have Bertrand and Marion on board. Both bring significant skills and experience to the company at a pivotal time. These two appointments will be key in supporting the growth of Tersan Pharmaceuticals Ltd and enabling the next phase of the company’s exciting journey” commented Mohammad Afshar, Chief Executive Officer of Tersan Pharmaceuticals Ltd.

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012. Further information is available at www.tersanpharm.com.

<p>The post Tersan Pharmaceuticals Ltd strengthens management team with appointments of VP Business Development and Chief Financial Officer first appeared on Tersan Pharmaceuticals Ltd.</p>

Focusing on a cohort of advanced & refractory cancer patients without tractable DNA alterations, the analysis concludes that the AI-transcriptional-based therapeutic recommendation-tool Onco KEM® is feasible and has the potential to identify potential therapeutic options for personalized cancer treatment.

The study included the analysis of 50 patients who had no Molecular Based Treatment Recommendation (MBTR) based on routinely used DNA Targeted Genomic Panel, Using RNA-Seq gene expression profiles and the AI-transcriptional-based therapeutic recommendation tool OncoKEM® developed by Tersan and OmiCure, the study showed that at least 2 targeted therapies were proposed for all patients.

“OmiCure and Ariana, with their RNA-based AI technology, have the potential to significantly improve outcomes for cancer patients who have no alternative therapeutic recommendations using DNA analysis only. We are encouraged by these initial results and look forward to assessing the clinical impact of RNA-based therapeutic recommendations in an upcoming clinical trial” commented Dr Pierre Saintigny, the study Principal Investigator, and Head of translational Medicine at the Centre Leon Bérard Cancer Center.

“I am excited by the opportunity of collaborating with the oncology team at the Centre Leon Bérard, a leading European cancer center”, said Thomas Turcat, OmiCure’s COO. “We remain committed to making a difference for particularly difficult patients with advanced metastatic disease where therapeutic alternatives are few and clinical outcomes are poor”.

More details about the study:

• •  50 patients with advanced refractory diseases were included in the PROFILER study (NCT01774409), with no MBTR based on a 90-tumor gene panel. The goal was to show the feasibility of MBTR using the AI-transcriptional-based therapeutic recommendation-tool OncoKEM to guide treatment recommendations.
• •  Most common diagnoses were breast cancers (21%, of which 63% were TNBC), followed by ovarian cancers (OC, 18%) and soft-tissue sarcomas (STS, 13%)
• •  All patients had at least 2 proposed treatments (range: 2-9) of targeted therapies among the top 10 ranked drugs in the Onco KEM reports
• •  Most frequently, proposed drugs among the top 10 were
  •     o In TNBC: palbociclib, talazoparib, infigratinib;
  •     o In ovarian cancer: bosutinib, sapanisertib, SAR125844;
  •     o In soft-tissue sarcomas: ipilimumab, cabozantinib, sapanisertib
• •  AI-transcriptional-based therapeutic recommendation tool OncoKEM is feasible and has the potential to expand personalized cancer treatment in patients with advanced & refractory diseases without tractable genomic alterations. The clinical relevance assessment is planned in an upcoming clinical trial.

More detailed information by clicking on the following links

• The full text of the abstract here or https://meetings.asco.org/abstracts-presentations/212349
• The ASCO poster
• The ASCO Slides
• More information about publications from CLB at ASCO2022 here

Full Press Release PDF

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine.

Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.
Further information is available at www.tersanpharm.com 

About OmiCure

OmiCure is a leading European digital health company, that develops and markets explainable AI-based therapeutic decision support software. OmiCure’s range of products provide physicians with the support they need when making complex cancer treatment decisions. OmiCure’s technology combines a proprietary advanced analytical explainable Artificial Intelligence xAI platform, with a comprehensive knowledgebase of scientific and medical advances. It has the power to analyze clinically relevant cancer biomarkers from DNA, RNA and protein profiles, from both solid and liquid biopsies.

This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile.

OmiCure provides worldwide access to state-of-the-art analyses to cancer centers, oncologists, and physicians, who aim to improve their therapeutic decision making in oncology. The xAI platform processes molecular biology data, including sequencing data from NGS platforms, and turns them into clinical insights.

For more information, visit: www.omicure.com

About CENTRE LEON BERARD anti-cancer center

CLB is one of the leading French Comprehensive Cancer Centres dedicated to excellent medical care, research and education and a member of the Federation of Cancer Centres (UNICANCER), OECI (Organisation of European Cancer Institutes)-certified. Ranked among the top 3 French cancer hospitals in terms of patient recruitment in clinical trials including CLB sponsored ones, CLB is certified by the French National Cancer (INCa) for early phase clinical trials (CLIP2 center).

CLB and its Molecular Tumor Board has a leading position and extensive experience in precision medicine by sponsoring large studies such as PROFILER (NCT01774409; > 4,000 patients included), PROFILER 02 (NCT03163732), MOST plus (NCT02029001) and more recently PLANET (NCT05099068) studies.

Finally, CLB is labelled by INCa since 2011 as an Integrated Cancer Research Site (SIRIC LYriCAN) and is actively involved in translational research with > 500 researchers on-site and 3 research Units including the Cancer Research Centre of Lyon (CRCL, UMR Inserm 1052 – CNRS 5286 – Centre Léon Bérard).

Contact

Tersan Pharmaceuticals Ltd
Marion SOTO
VP business Development
M.soto@tersanpharm.com

<p>The post Tersan Pharmaceuticals Ltd, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients. first appeared on Tersan Pharmaceuticals Ltd.</p>

Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference

Pushing the promise of AI designed Precision Medicine Parkinson’s Disease Dementia (PDD) therapy closer to the finish line, Tersan, the AI Drug Development Company and ANAVEX Life Sciences announced positive ANAVEX®2-73 Phase II results.

Cambridge, Mass. and Paris, France, March 21st, 2022. Tersan Pharmaceuticals Ltd, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference.

MDS-UPDRS Total score improved significantly for patients treated with ANAVEX®2-73 high oral once-daily dose compared to placebo. The improvement is clinically relevant, corresponding to a relative improvement of 18.9% over 14 weeks. Balanced and global improvements were observed within all MDS-UPDRS sub-scores Part I-IV.

SIGMAR1 mRNA expression biomarker, previously identified using Tersan’s eXplainable Artificial Intelligence (xAI) KEM® technology, was significantly increased in ANAVEX®2-73 treated patients vs. placebo over the course of treatment (p=0.035). In addition, this biomarker was significantly associated with improvements of MDS-UPDRS scores and cognitive efficacy endpoints CDR system.

 Age,  certain neurophysiological measures, and high systolic blood pressure at baseline were identified with an increased response for the endpoints. 

This finding builds on the KEM® AI-driven precision medicine clinical development platform of ANAVEX®2-73, where the SIGMAR1 mRNA expression biomarker as previously identified as a potential biomarker (Hampel et al, Alzheimer Dement (N Y). 2020; 6(1): e12013) is characterized across multiple indications, including Alzheimer’s Disease and Rett syndrome.

“The reported strong positive biomarker and clinical results in Parkinson’s Disease Dementia, building on previously reported positive results in RETT syndrome and Alzheimer’s disease, further illustrate the power of KEM® Explainable AI to accelerate precision medicine drug development building on in-depth understanding of the intersection between SIGMAR1 molecular pathways and disease biology” said Mohammad Afshar, M.D., Ph.D., Chief Executive Officer of Tersan Pharmaceuticals Ltd.

 

More information

Poster: ANAVEX®2-73 (blarcamesine): Analysis Of Movement (MDS-UPDRS) And Cognitive (CDR System) Pharmacodynamic Biomarker Outcome Measures of Placebo-Controlled Phase 2 Trial in 132 Parkinson’s Disease Dementia Patients J. Kulisevsky, T. Fadiran, E. Hammond, C. Missling, C. Williams, F. Parmentier, M. Kindermans & M. Afshar. Proceedings of the AD/PD 2022 International Conference on Alzheimer’s & Parkinson’s Diseases and related neurological disorders. Barcelona, Spain, March 15–20, 2022 – click here

ANAVEX’s press release – click here

About Tersan Pharmaceuticals Ltd

Tersan Pharmaceuticals Ltd is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Tersan helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. 

Tersan routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Tersan helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Tersan has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United Kingdom since 2012.

Further information is available at www.tersanpharm.com.

 

<p>The post Anavex Life Sciences and Tersan Pharmaceuticals Ltd present positive phase II clinical and biomarker data at the AD/PD 2022 International Conference first appeared on Tersan Pharmaceuticals Ltd.</p>

<p>The post Cyclerion Therapeutics and Tersan Pharmaceuticals Ltd Announce an Artificial Intelligence-driven Precision Medicine Collaboration first appeared on Tersan Pharmaceuticals Ltd.</p>

<p>The post Tersan appoints pharmaceutical industry drug development veteran first appeared on Tersan Pharmaceuticals Ltd.</p>

<p>The post Tersan announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi first appeared on Tersan Pharmaceuticals Ltd.</p>